Stille (STIL) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
30 Oct, 2026Executive summary
Q3 net sales were MSEK 170.6, up 22.9% YoY, with 16.5% organic growth; EBIT margin before non-recurring items rose to 14.4% from 12.5%.
Rolling 12-month sales reached MSEK 711.4, exceeding MSEK 700 for the first time.
Improved availability and shorter delivery times supported growth; operating cash flow rose to MSEK 34 from MSEK 10.
Financial highlights
Q3 revenue was MSEK 170.6, up 22.9% YoY; constant-currency growth was 21.5%, including 16.5% organic growth.
EBITDA before non-recurring items rose 29% to MSEK 33.7; EBIT before non-recurring items rose 42% to MSEK 24.5.
Gross margin was 49.9%, or 50.5% excluding acquisition effects, with improvement mainly from favorable mix.
Operating cash flow was MSEK 34 versus MSEK 10 in Q3 2025; Jan-Sep operating cash flow was MSEK 91.2.
Jan-Sep sales were MSEK 536.5 versus MSEK 392.7; profit after tax was MSEK 66.0 versus MSEK 25.5.
Outlook and guidance
Long-term targets remain 10% organic growth, a 25% EBITDA margin and net debt/EBITDA below 3x.
Priorities include scaling instrument supply, strengthening commercial execution and customer access, and building capabilities and infrastructure for growth.
Plans include building on imagiQ3 momentum, pursuing share gains and complementing organic growth through selective acquisitions.
Tables growth of ~30% in 2026 is not expected to repeat in 2027; further growth and share gains remain the aim.
Latest events from Stille
- Premium surgical instruments and tables drive strong growth and global expansion.STIL
Company presentation - Record Q2 2026 sales and profit growth driven by strong demand and operational execution.STIL
Q2 2026 - Strong financial growth and premium positioning drive expansion in surgical instruments and tables.STIL
Company presentation - Premium surgical solutions provider achieves strong growth and margins, expanding via acquisitions.STIL
Investor presentation - Q1 2026 saw 39% revenue growth and margin expansion, driven by demand and strategic acquisition.STIL
Q1 2026 - Q4 sales up 8.5% with strong surgical tables demand; outlook for 2026 remains positive.STIL
Q4 2025 - Sales rose 8.5% in Q3, but margins fell; supply chain and growth outlook improve for 2026.STIL
Q3 2025 - Sales declined 12.6% but margin and order intake improved; UK acquisition to boost growth.STIL
Q2 2025 - Q3 sales surged 82% with margin gains, led by Fehling integration and strong instrument growth.STIL
Q3 2024